TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02718326
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00627016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule, orally, once daily for 4 weeks
Study: NCT02505880
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
Study: NCT01659008
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002689
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02813200
Drug: Seretide® Diskus® 500/550 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every day during 7 days
Study: NCT02813200
Drug: Ultibro® Breezhaler® 110/50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every day during 7 days
Study: NCT02813200
Drug: Spiriva® Respimat® 2,5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every day during 7 days
Study: NCT02238444
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study: NCT00782769
Drug: Oxybutinyn Vaginal Ring 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00782769
Drug: Oxybutinyn Vaginal Ring 6mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01218178
Drug: Saline hydration plus NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
Study: NCT01687712
Drug: Gonal-f® RFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Study: NCT02573155
Drug: Dose 1, AZD8871 50 μg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Dose 2, AZD8871 100 μg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Dose 3, AZD8871 300 μg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Dose 4, AZD8871 600 µg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Dose 5, AZD8871 1200 µg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Dose 6, AZD8871 1800 μg (Part 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT02573155
Drug: Treatment A, AZD8871 dose A (Part 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study: NCT00387686
Drug: rhBMP-2/CPM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02257983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
Study: NCT02646124
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg by mouth two times a day, #20
Study: NCT02646124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 placebo capsules
Study: NCT01520012
Drug: YH4808 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
Study: NCT01762852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
Study: NCT03787498
Drug: PLX2853
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT01520012
Drug: YH4808 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
Study: NCT01520012
Drug: YH4808 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
Study: NCT01520012
Drug: YH4808 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
Study: NCT01520012
Drug: YH4808 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
Study: NCT00896571
Drug: Ethinylestradiol/Gestogene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study: NCT01250379
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (doublets not allowed)
Study: NCT02358642
Drug: Angiotensin converting enzyme inhibitor (Lisinopril)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00574132
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study: NCT02358642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02270242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Study: NCT03992404
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT03992404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
Study: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
Study: NCT00829530
Drug: Altace® 10 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT00256230
Drug: Disulfiram (DSF)
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
Study: NCT02335099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill twice a day for 6 months
Study: NCT03363815
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT00121550
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02586168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01911156
Drug: Continue NA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed NA during the 72 week study period
Study: NCT01911156
Drug: Discontinue NA Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue NA Treatment
Study: NCT00006421
Drug: 2-Fluorodeoxyglucose
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01452802
Drug: OMM (Optimal Medical Management)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
Study: NCT00223145
Drug: Androgen blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration : 6 months
Study: NCT00583453
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study: NCT00583453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study: NCT00800501
Drug: sNN0029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ICV infusion at one of three dose levels
Study: NCT00800501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ICV infusion
Study: NCT00941265
Drug: levodopa and benserazide
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
Study: NCT00941265
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
Study: NCT01314716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZLI administered via nebulizer three times daily
Study: NCT00805480
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 was administered intravenously.
Study: NCT00805480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AIN457 was administered intravenously.
Study: NCT00865072
Drug: GLUCOPHAGE® XR 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT04994119
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study: NCT01928381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind placebo capsules to match AZD5213 and pregabalin
Study: NCT04197115
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT04197115
Drug: Complex B
Normalized name: Complex B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
Study: NCT00002827
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00840866
Drug: Cefzil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT02135887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6# TID with meal
Study: NCT03589313
Drug: GLPG3067 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3067 film coated tablets provided at Day 1.
Study: NCT01411085
Drug: Risperidone + Desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04654143
Drug: BVL-GSK098 capsule, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QD
Study: NCT00573443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study: NCT01443195
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation).
Study: NCT03039426
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 75 mg intramuscular, 2 hours postoperation
Study: NCT01564862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching capsules
Study: NCT03809611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01240161
Drug: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will have 0-3 or more FLT-PET brain scans.
Study: NCT02083783
Drug: TRI102
Approvals — FDA: no, EMA: no, PMDA: no
Description: formulation containing active moiety (amphetamine)
Study: NCT01762878
Drug: GSK2269557
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
Study: NCT01762878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for oral inhalation once daily using DIKUS device
Study: NCT04154735
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A medication used as chemotherapy and to suppress the immune system
Study: NCT00004897
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004897
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00481650
Drug: Leios/Alesse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02331823
Drug: Streptomycin injectable
Normalized name: streptomycin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
Study: NCT01693523
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by mouth two times a day (200 mg/day).
Study: NCT00938314
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
Study: NCT02265874
Drug: Placebo to Habitrol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01427972
Drug: LY2623091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01440803
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
Study: NCT01427972
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00107237
Drug: AEE788
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
Study: NCT00959816
Drug: ABT-614
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
Study: NCT01670890
Drug: TMZ plus CDDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
Study: NCT00100464
Drug: 5HTP
Normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03557281
Drug: GSK3036656
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3036656 will be administered
Study: NCT04080375
Drug: Dinoprostone 3 mg
Normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
Study: NCT00891605
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study: NCT04080375
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patient will take one vaginal tablet of placebo 1 hour before surgery
Study: NCT03378076
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
Study: NCT03378076
Drug: TAcs 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
Study: NCT02908516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
Study: NCT02438709
Drug: COX-2 inhibitor
Normalized name: COX-2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral COX-2 inhibitor intake 60mg qd
Study: NCT04677712
Drug: CCH-aaes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
Study: NCT04677712
Drug: INhance®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
Study: NCT02995720
Drug: Fimasartan/Amlodipine combination drug, Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01726348
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
Study: NCT02368717
Drug: Placebo Enema
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03756038
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
Study: NCT00783094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily
Study: NCT02469090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00152542
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
Study: NCT00152542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iNO given for days 1-7
Study: NCT00466401
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no